Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor
This article was originally published in RPM Report
It's a buyer's market for type 2 diabetes drugs, and you can thank FDA for that. At least, that is the sentiment of business development executives from Big Pharma. Transaction data in 2008 back up that view.
You may also be interested in...
Zydus Cadila scores a regulatory approval in India for Lipaglyn, a PPAR alpha/gamma dual agonist, but in a class known for cardiovascular risks the product will likely be under close scrutiny.
An unusual footnote in FDA’s approval letter for Takeda’s long-delayed diabetes medicine means that the company won’t have to worry about losing five-year exclusivity on the molecule.
Tougher regulatory hurdles introduced three years ago extended the timelines for successful diabetes drug development, discouragiing investment and partnering activity. An ever-increasing incidence of diabetes, metabolic disorders, and obesity continues to drive innovation and the development of new medicines – but with less emphasis on novel mechanisms.